组织蛋白酶B
嵌合抗原受体
癌症研究
细胞毒性T细胞
半胱氨酸蛋白酶
抗原
组织蛋白酶
体外
组织蛋白酶
化学
细胞生物学
体内
癌症
组织蛋白酶L
组织蛋白酶D
生物
功能(生物学)
表型
机制(生物学)
下调和上调
汽车T细胞治疗
蛋白酵素
肿瘤抗原
蛋白酶
分子生物学
癌细胞
免疫学
作者
Kenneth A. Dietze,Kiet Nguyen,Aashli Pathni,Frank Fazekas,Wenxiang Sun,Ethan Rosati,Jillian M. Baker,Maday Galeana Figueroa,Etse Gebru,Daniel Yamoah,Rediet Mulatu,Alexander Wang,Aaron P. Rapoport,David H. Lum,Xiaoxuan Fan,Sabarinath V. Radhakrishnan,Djordje Atanackovic,Arpita Upadhyaya,Tim Luetkens
标识
DOI:10.1038/s41392-026-02654-z
摘要
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in cancer treatment. Nevertheless, most patients receiving CAR T cells relapse within 5 years of treatment. CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism in which cell surface proteins transfer from tumor cells to CAR T cells. CMT results in the emergence of antigen-negative tumor cells, which can evade future CAR detection, and antigen-positive CAR T cells, which have been suggested to cause CAR T-cell fratricide and exhaustion. Whether CMT indeed causes CAR T-cell dysfunction and the molecular mechanisms conferring CMT remain unknown. Using a selective degrader of trogocytosed antigen in CAR T cells, we show that the presence of trogocytosed antigen on the CAR T-cell surface directly causes CAR T-cell fratricide and exhaustion. By performing small molecule screening using a custom high-throughput CMT screening assay, we found that the cysteine protease cathepsin B is essential for CMT and that inhibition of cathepsin B is sufficient to prevent CAR T-cell fratricide and exhaustion, leading to improved long-term in vitro and in vivo CAR T-cell persistence and in vitro antitumor activity. Our data demonstrate that it is feasible to separate CMT from cytotoxic activity, that CAR T-cell persistence, a key factor associated with clinical CAR T-cell efficacy, is directly linked to cathepsin B activity in CAR T cells, and that it is possible to improve CAR T-cell function through selective inhibition of CMT.
科研通智能强力驱动
Strongly Powered by AbleSci AI